Every day our researchers read through the top innovation headlines and provide their expert opinions on important developments and industry news. Our analysts then evaluate news based on potential importance ranking the developments from Truly Disruptive to Ignore.
On Fridays we highlight our Lux Take on the top news for the week. Check out our thoughts on the latest emerging technology and innovation news for the past week below.
B2B agrifood platform Tridge ends $60 million Series C to expand its fulfillment services
"Huntington's disease (HD) is a slow and fatal neurodegenerative disease with no cure in sight. HD is caused by a mutation in the Huntingtin gene. This also makes it the perfect candidate to address with gene therapy. However, an unsolved challenge was how to measure therapeutic efficacy before the presentation of symptoms, by which time, it is already too late to treat. Here, the researchers developed a noninvasive way to track efficacy, called inflow-based vascular-space-occupancy (iVASO) MRI. Companies, while this is an early-stage study in mice, and more data will be needed in human studies, the digital biomarker opportunity goes beyond consumer health to tracking clinical efficacy in pre-symptomatic stages of potentially fatal diseases."